Sandu Pharmaceuticals Ltd.

Healthcare · Pharmaceuticals & Biotechnology

BSE: 524703
₹36.20
▲ 0.36 (1.00%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
59/100
Moderate
Valuation
88/100
Undervalued
Momentum
45/100
Neutral

QVM read Cheap on its own multiples Quality Moderate, Valuation Undervalued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹35 Cr
PE (TTM)
18.5
Industry median 36.1 (152 companies)
Price to Book
0.8
PEG (TTM)
1.0
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-35.8
Free Cash Flow
₹5 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
60.87%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-8.01%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
4.16%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-86.81%
as of March 31, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-1.86%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
2.43
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.01
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
24.17
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
0.26%
as of March 31, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
2.39%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
4.01%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
2.55%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
6.09%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
3.26%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

3 of 6 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.01)
  • No Return on equity is 15% or more (3.3%)
  • Yes Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

2 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

0 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

2 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Undervalued (below its own historical PE range))
  • Yes Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
1.0%
Low 36.1600 · High 37.4400
1W return
-2.4%
Low 35.8000 · High 37.9700
1M return
-4.1%
Low 35.2000 · High 39.5000
52W return
-35.8%
Low 33.6500 · High 41.0000
Lifetime High ₹81.8000 (April 25, 2022)
Lifetime Low ₹6.5200 (Nov. 21, 2008)

Full price history and technicals →

EMA & SMA

Bullish0
Bearish6
5D
36.4
10D
36.7
20D
37.5
50D
42.2
100D
49.0
200D
59.9

Delivery and volume

Day avg. delivery
98.7%
Week avg. delivery
95.7%
Month avg. delivery
91.3%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

36.60
Pivot
First resistance37.04
Second resistance37.88
Third resistance38.32
First support35.76
Second support35.32
Third support34.48
Day RSI34.9
Day MFI38.8
Day MACD-1.43
Day MACD signal-1.74

Beta

1M0.17
3M-0.11
1Y-0.11
3Y0.41

Price change analysis

↓ -4.1%
Over 1 Month
LowHigh
35.2039.50
↓ -35.8%
Over 3 Months
LowHigh
33.6541.00
↓ -35.8%
Over 6 Months
LowHigh
33.6541.00
↓ -35.8%
Over 1 Year
LowHigh
33.6541.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 18.5 (own history: 26.6–45.4)
Undervalued (below its own historical PE range)
Revenue (June 30, 2026)
₹16 Cr
Net profit (June 30, 2026)
₹— Cr
Basic EPS (June 30, 2026)
₹0.3700

Ranks #160 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter37.79%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 37.79% in Jun 2026 qtr

All shareholding details →

DateClientDealActionQuantityPriceExchange
19 Mar 2024 DPS TRADELINK PRIVATE LIMITED Bulk Sell 104,061 55.8500 BSE
19 Mar 2024 TRANS SCAN SECURITIES PVT LTD Bulk Buy 106,000 55.8800 BSE
9 Jul 2021 PORINJU VELIYATH Bulk Sell 43,500 51.9900 BSE
20 Mar 2009 REENA JASVANTBHAI JANI Bulk Buy 45,000 7.7500 BSE
20 Mar 2009 AMI STOCK SHARE BROKERS PLTD Bulk Sell 45,001 7.8800 BSE
17 Mar 2009 RAMESH G GOKANI Bulk Buy 45,000 7.8500 BSE
9 Feb 2009 RAMESH G GOKANI Bulk Sell 45,000 7.9500 BSE
9 Feb 2009 AMI STOCK SHARE BROKERS PLTD Bulk Buy 45,000 7.9500 BSE
30 Jan 2009 RAMESH G GOKANI Bulk Buy 45,000 8.4000 BSE
30 Jan 2009 AMI STOCK SHARE BROKERS PLTD Bulk Sell 45,000 8.4000 BSE

All bulk and block deals →

Ex-dateSubjectPer share (₹)Record date
— Final Dividend - Rs. - 1.0000 — —

Corporate Announcements

All 5 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
30 Sep 2026 Company Update Sandu Pharmaceuticals Ltd - 524703 - Intimation To The Holders Of Physical Securities To Furnish PAN And KYC Details
12 Sep 2026 AGM/EGM Sandu Pharmaceuticals Ltd - 524703 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
12 Sep 2026 Company Update Sandu Pharmaceuticals Ltd - 524703 - Announcement under Regulation 30 (LODR)-Change in Directorate
12 Sep 2026 Company Update Sandu Pharmaceuticals Ltd - 524703 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
11 Sep 2026 AGM/EGM Sandu Pharmaceuticals Ltd - 524703 - Shareholder Meeting / Postal Ballot-Outcome of AGM

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.01)
  • Comfortable interest coverage (24.2x)
  • Healthy liquidity (Current Ratio 2.43)

Weaknesses

  • Low Return on Equity (3.3%)
  • Thin net profit margin (0.3%)
  • Declining revenue YoY (-1.9%)
  • Declining profit YoY (-86.8%)

Opportunities

  • Trading below book value (PB 0.83)

Threats

  • Down 35.8% over the past year

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Sandu Pharmaceuticals Ltd.

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.